| 영문 | cell-mediated immunity | 한글 | 세포매개면역 |
|---|---|---|---|
| 설명 | 면역이란 신체를 외부의 물질로부터 보호하는 행위를 말한다. 여기에는 특이적 면역과 비특이적 면역의 두 가지가 있다. 비특이적 면역이라함은 특정한 물질에 관계하는 면역이 아니라 특정 대상이 없이 모든 외부 물체에 작용할 수 있는 면역을 말한다. 여기에는 소변의 흐름, 눈물의 흐름, 피부의 비투과성 등의 기계적인 것도 포함되고 피속에 돌아다니는 세포 중에서 비특이적으로 외부의 물질을 포식하는 세포들(예를 들면 큰포식세포(macrophage)의 활동도 포함이 된다. 세포매개면역이란 특이한 물질을 감지할 수 있는 세포를 생성하게 하여 그것으로 하여금 그 물질을 포식하게 하는 것을 말한다. |
||
| 영문 | receptor | 한글 | 수용체 |
|---|---|---|---|
| 설명 | 세포질내 또는 세포표면에 존재하는 분자구조로서 특이물질과 선택적으로 결합하며 결합에 의해 특이한 생리적 작용을 나타낸다. 펩티드호르몬, 신경전달물질, 항원, 보체, 면역글로불린에 대한 세포표면 수용체와 스테로이드에 대한 세포질내 수용체가 있다. |
||
| CML | carboxymethyl lysine; cell-mediated lymphocytotoxicity; cell-mediated lympholysis; central motor lat... |
|---|---|
| ER | efficiency ratio; epigastric region; ejection rate; electroresection; emergency room; endoplasmic re... |
| RAR | rapidly adapting receptor; rat insulin receptor; retinoic acid receptor; right arm reclining; right ... |
| ADCC cell | Antibody Dependent Cellular(= Cell-Mediated) Cytotoxicity cell |
| CMI | 1) Cornell Medical Index 2) Cell-Mediated Immunity |
| RME | Receptor-mediated endocytosis |
|---|---|
| RHAMM | receptor for hyaluronan mediated motility |
| ADCC | Antibody Dependent Cell-Mediated Cytotoxicity |
| ADCC | Antibody-dependent cell-mediated cytolysis |
| CML | Cell Mediated Lympholysis |
| receptor mediated endocytosis | Endocytosis of molecules by means of a specific receptor protein that normally resides in a coated pit, but may enter this structure after complex formation occurs. The structure then forms a coated vesicle that delivers its contents to the endosome whence it may enter the cytoplasm or the lysosomal compartment. Many bacterial toxins and viruses enter cells by this route. (18 Nov 1997) |
|---|
| cell-mediated immunity | <immunology> Immune response that involves effector T lymphocytes and not the production of humoral antibody. Responsible for allograft rejection, delayed hypersensitivity and in defence against viral infection and intracellular protozoan parasites. (26 Mar 1998) |
|---|---|
| cell-mediated reaction | Immunological reaction of the delayed type, involving chiefly T lymphocytes, important in host defense against infection, in autoimmune diseases, and in transplant rejection. See: skin test. (05 Mar 2000) |
| endocytosis | Uptake of material into a cell by the formation of a membrane bound vesicle. (18 Nov 1997) |
| ligand induced endocytosis | The formation of coated pits and then coated vesicles as a consequence of the interaction of ligand with receptors, which then interact with clathrin and associated proteins (coatomers) on the cytoplasmic face of the plasma membrane and come together to form a pit. Not all coated vesicle uptake of receptors requires receptor occupancy. (18 Nov 1997) |
| acetylcholine receptor antibodies | <neurology, investigation> A test used to measure the amount of antibodies to acetylcholine receptors on nerve endings. This is a diagnostic test for myasthenia gravis. A normal value is no antibodies in the bloodstream. Acetylcholine receptor (AChR) binding autoantibodies (i.e. Antibodies reactive with several epitopes other than the binding site for acetylcholine or alpha-bungarotoxin) are present in approximately 88% of patients with generalised myasthenia gravis, 70% of ocular myasthenia and in approximately 80% of myasthenia gravis in remission. Although serum concentrations of AChR binding autoantibodies do not in general correlate well with severity of weakness, there is typical decrease in concentration as weakness improves with immunosuppressive therapy. AChR blocking autoantibodies (i.e., antibodies reactive with the AChR binding site) are present in about 50% of patients with myasthenia gravis, 30% with ocular myasthenia gravis and 20% of myasthenia gravis in remission, AChR blocking autoantibodies are the only AChR autoantibodies present in about 1% of myasthenia gravis. AChR modulating autoantibodies (i.e., autoantibodies which cross-link AChRs and cause their removal from muscle membrane surfaces) are present in more than 90% of myasthenia gravis and occasionally are the only AchR autoantibodies detectable in mild, recent onset or ocular-restricted myasthenia gravis. Results for AChR modulating autoantibodies can be transiently false-positive due to curare-like drugs used during general anesthesia. AChR autoantibodies of one or more types are found in at least 80% of ocular myasthenia gravis. Although generally absent in neurological conditions other than myasthenia gravis(and consequently unlikely to cause confusion in neurodiagnosis), false-positive results for AChR autoantibodies occasionally occur in primary biliary cirrhosis, tardive dyskinesia, autoimmune thyroiditis, the elderly, amyotrophic lateral sclerosis patients treated with cobra venom and patients with thymoma in the absence of myasthenia gravis. Approximately 1% of patients with rheumatoid arthritis treated with D-penicillamine develop AChR autoantibodies and myasthenia gravis, both of which disappear when the drug is discontinued. Babies born to ~10% of myasthenia gravis mothers have a transient neonatal form of myasthenia gravis that responds well to anticholinesterase therapy and usually remits within 1 month as maternal IgG disappears. (29 Dec 1997) |
| amino acid receptor | <biochemistry> Ligand gated ion channels with specific receptors for amino acid transmitters. An extended protein superfamily that also includes subunits of the nicotinic acetylcholine receptor. (18 Nov 1997) |
| AMPA receptor | <cell biology> Glutamate operated ion channel. See: excitatory amino acid receptor channels. (05 Feb 1998) |
| ANP receptor | <molecular biology> Family of 3 receptors for atrial natriuretic peptide. ANP A and ANP B have intracellular guanylate cyclase and protein kinase like domains. ANP C, shares the extracellular ligand binding and transmembrane domains, but lacks the functional intracellular domains and is not thought to be involved in signal transduction. (18 Nov 1997) |
| asialoglycoprotein receptor | A surface receptor found in hepatocytes that binds galactose-terminal glycoproteins; thus, this receptor removes those proteins from circulation and they are in turn acted upon by hepatocyte lysosomes. (05 Mar 2000) |
| auditory receptor cells | Columnar cell's in the epithelium of the organ of Corti, having hairs (stereocilia) on their apical ends. See: Corti's cells. (05 Mar 2000) |
| beta-adrenergic receptor blocking agent | A class of drugs that compete with beta-adrenergic agonists for available receptor sites; some compete for both b1 and b2 receptors (e.g., propranolol) while others are primarily either b1 (e.g., metoprolol) or b2 blockers; used in the treatment of a variety of cardiovascular diseases where beta-adrenergic blockade is desirable. Synonym: beta-adrenergic receptor blocking agent, beta-adrenoreceptor antagonist, beta-blocker. (05 Mar 2000) |
| beta-adrenergic receptor kinase | <enzyme> Cyclic-AMP protein kinase which specifically phosphorylates the agonist-occupied form of beta-adrenergic receptor Registry number: EC 2.7.1.- Synonym: beta-ar kinase, beta-adrenergic receptor kinase 1, g-protein-coupled receptor kinase 2, grk2 (kinase), beta-adrenergic receptor kinase 2, beta-ar kinase 2 (26 Jun 1999) |
| cAMP receptor protein | catabolite (gene) activator protein |
| GABA receptor | <physiology> Ligand gated chloride ion channel forming receptor opened by gamma aminobutyric acid. Two distinct types: A and B. A receptor: One of a family of neurotransmitter receptors with fast intrinsic ion channels that includes the glycine receptor and the nicotinic acetylcholine receptor. Distinct from another major receptor family, the muscarininc acetylcholine receptor and rhodopsin, with no intrinsic ion channel. The A receptor is specifically blocked by bicuculline. It consists of two pairs of protein chains forming an A2B2 complex, the A chains bind benzodiazepine and the B chains bind GABA. The 4 subunits are thought to form a tight group with the chloride channel in the middle. There is considerable similarity between the amino acid sequences of the receptor subunits and those of the nicotinic acetylcholine receptor suggesting that both receptors are derived from some evolutionary ancestor. See: amino acid receptor superfamily. B receptor: Brain receptor (80 kD) for the inhibitory neurotransmitter gamma amino butyric acid. Differs from the A receptor both in agonist specificity (baclofen is a specific agonist) and its effects on cells. It modulates intracellular calcium levels through a Go mediated effect on N type calcium channels and also lowers intracellular cAMP levels by an effect on adenylyl cyclase, thereby reducing the secretion of catecholamines. (05 Jan 1998) |
| p60 tumour necrosis factor receptor-associated kinase | <enzyme> Interacts with and causes phosphorylation of the cytoplasmic domain of the tnf receptor Registry number: EC 2.7.10.- Synonym: p60 tnf receptor-associated kinase, p60-trak (26 Jun 1999) |
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|